FATE - NASDAQ
Fate Therapeutics, Inc.
$2.25
-13%Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
At a Glance
Live Snapshotfate
Research Development Expenses
Last Annual Value
107.83M
3-Year CAGR
-30%
5-Year CAGR
-3%
10-Year CAGR
18%
Fate Therapeutics, Inc. Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Fate Therapeutics, Inc. NASDAQ:FATE | 107.83M | -14.5% | -12.9% | 15.1% | |
 Acumen Pharmaceuticals, Inc. NASDAQ:ABOS | 104.89M | 35.3% | 53.5% | N/A | |
 Prelude Therapeutics Incorporated NASDAQ:PRLD | 94.30M | -3.0% | 1.7% | N/A | |
 Actuate Therapeutics Inc NASDAQ:ACTU | 10.29M | -22.0% | N/A | N/A | |
 Elicio Therapeutics, Inc. NASDAQ:ELTX | 24.90M | 3.2% | -12.5% | N/A | |
 Applied Therapeutics, Inc. NASDAQ:APLT | 48.74M | -3.3% | -4.9% | N/A | |
 Forte Biosciences, Inc. NASDAQ:FBRX | 58.25M | 38.6% | 33.3% | 7.9% | |
 Seres Therapeutics, Inc. NASDAQ:MCRB | 49.06M | -25.3% | -19.1% | -5.0% | |
 Tonix Pharmaceuticals Holding Corp. NASDAQ:TNXP | 44.49M | -19.9% | -8.4% | 4.5% | |
 Nkarta, Inc. NASDAQ:NKTX | 90.43M | -0.2% | 7.4% | N/A | |
 Cassava Sciences, Inc. NASDAQ:SAVA | 26.59M | -33.3% | 1.4% | 11.2% |
Fate Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your FATE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.